Previous 10 | Next 10 |
Gainers: ZIOPHARM Oncology (NASDAQ:ZIOP) +39%, RenovoRx (NASDAQ:RNXT) +17%, Sigilon Therapeutics (NASDAQ:SGTX) +17%, Acumen Pharmaceuticals (NASDAQ:ABOS) +15%, NeuroOne Medical Technologies (NASDAQ:NMTC) +7%. Losers: CorMedix (NASDAQ:CRMD) -25...
RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborate to de...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) rose more than 10% on Wednesday. The stock, which closed at $1.63 on Tuesday, opened at $1.65 on Wednesday and rose as high as $1.84 in midday trading. But it's still closer to its 52-week low of $1.26 than it is to its 52-week high of $5.9...
BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual i...
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele B...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: ZIOPHARM Oncology, Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. ZIOPHARM Oncology Inc (NASDAQ: ZIOP) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: ZIOPHARM Oncology Inc (ZIOP) Q2 2021 Earnings Call Transcript
ZIOPHARM Oncology, Inc. (ZIOP) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Adam Levy – Executive Vice President-Corporate Development and Investor Relations Heidi Hagen – Interim Chief Executive Officer Raffaele Baffa – Chief Medical Of...
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and e xten...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...